Shire to buy FerroKin for up to $325m bringing in iron chelator candidate

15 Mar 2012

• By Sukaina Virji

Shire is buying privately-held US biotech company FerroKin BioSciences for $100 million up front and $225 million in milestones as a "strategic step in building its haematology business". FerroKin brings a "differentiated" development candidate to Shire's portfolio, the Phase II-stage iron chelator FBS0701, it added.

FBS0701 is a once-daily oral capsule in development for the treatment of iron overload due to chronic blood transfusions in...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

Start your 7-day free trial
Explore trusted news, analysis, and insights
Access comprehensive global coverage
Enjoy instant access – no credit card required

Start Free Trial

Already a subscriber?

Merck & Co.’s Enlicitide Poised To Be First Oral PCSK9 Inhibitor To Market

09 Jun 2025

• By Jessica Merrill

The company announced positive data from two Phase III trials testing the cholesterol-lowering medicine.

In Brief: Tourmaline Reports Positive Topline Phase II Results for Pacibekitug In CKD

21 May 2025

• By Sushmita Panda

Based on first positive results for any quarterly IL-6 inhibitor, company plans to initiate Phase III cardiovascular outcomes trial.

In Brief: Essence Raises Ionis Tryngolza Hypertriglyceridemia Filing Hopes

20 May 2025

• By Sushmita Panda

Tryngolza has met endpoints in a moderate hypertriglyceridemia trial. Positive results in severe disease in Q3 could allow for a filing for a broader patient population than its currently approved indication of familial chylomicronemia syndrome.

Regeneron Wins PCSK9 Court Battle Against Amgen

16 May 2025

• By Alaric DeArment

A federal court jury found Amgen liable for violating antitrust laws in allegedly preventing Praluent from competing against Repatha.

Lilly Looks For Muscle-Sparing Candidates In Pact With Juvena

12 Jun 2025

• By Joseph Haas

Deal Snapshot: Including its internal efforts with bimagrumab, Lilly has been seeking a muscle-sparing therapy to complement GLP-1 obesity drugs, such as Zepbound.